“Phase 2 Study of Cemiplimab in Patients with Advanced Cutaneous Squamous Cell Carcinoma (CSCC): Longer Follow-Up”, J of Skin, vol. 4, no. 6, p. s124, Oct. 2020, doi: 10.25251/skin.4.supp.124.